![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C8A |
Gene summary for C8A |
![]() |
Gene information | Species | Human | Gene symbol | C8A | Gene ID | 731 |
Gene name | complement C8 alpha chain | |
Gene Alias | C8A | |
Cytomap | 1p32.2 | |
Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | P07357 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
731 | C8A | NAFLD1 | Human | Liver | NAFLD | 6.58e-14 | 1.25e+00 | -0.04 |
731 | C8A | S41 | Human | Liver | Cirrhotic | 3.82e-02 | 4.49e-01 | -0.0343 |
731 | C8A | S43 | Human | Liver | Cirrhotic | 1.26e-06 | -2.58e-01 | -0.0187 |
731 | C8A | HCC1_Meng | Human | Liver | HCC | 3.82e-88 | -9.69e-02 | 0.0246 |
731 | C8A | HCC2_Meng | Human | Liver | HCC | 9.13e-08 | -3.28e-01 | 0.0107 |
731 | C8A | cirrhotic1 | Human | Liver | Cirrhotic | 3.17e-07 | -3.17e-01 | 0.0202 |
731 | C8A | cirrhotic2 | Human | Liver | Cirrhotic | 1.83e-07 | -3.15e-01 | 0.0201 |
731 | C8A | cirrhotic3 | Human | Liver | Cirrhotic | 6.73e-03 | -3.23e-01 | 0.0215 |
731 | C8A | Pt13.a | Human | Liver | HCC | 2.91e-05 | -3.03e-01 | 0.021 |
731 | C8A | Pt13.b | Human | Liver | HCC | 2.20e-03 | -2.86e-01 | 0.0251 |
731 | C8A | Pt14.d | Human | Liver | HCC | 3.45e-02 | -2.26e-01 | 0.0143 |
731 | C8A | S015 | Human | Liver | HCC | 1.45e-03 | 4.05e-01 | 0.2375 |
731 | C8A | S027 | Human | Liver | HCC | 4.12e-09 | 1.10e+00 | 0.2446 |
731 | C8A | S028 | Human | Liver | HCC | 7.54e-16 | 7.56e-01 | 0.2503 |
731 | C8A | S029 | Human | Liver | HCC | 7.57e-27 | 1.43e+00 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001593122 | Thyroid | ATC | nucleobase-containing compound transport | 122/6293 | 222/18723 | 4.30e-11 | 1.41e-09 | 122 |
GO:000170126 | Thyroid | ATC | in utero embryonic development | 183/6293 | 367/18723 | 6.62e-11 | 2.11e-09 | 183 |
GO:007190025 | Thyroid | ATC | regulation of protein serine/threonine kinase activity | 176/6293 | 359/18723 | 8.35e-10 | 2.17e-08 | 176 |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:000646925 | Thyroid | ATC | negative regulation of protein kinase activity | 114/6293 | 212/18723 | 1.06e-09 | 2.69e-08 | 114 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
GO:003367325 | Thyroid | ATC | negative regulation of kinase activity | 122/6293 | 237/18723 | 9.19e-09 | 1.94e-07 | 122 |
GO:000931426 | Thyroid | ATC | response to radiation | 210/6293 | 456/18723 | 1.69e-08 | 3.39e-07 | 210 |
GO:007145325 | Thyroid | ATC | cellular response to oxygen levels | 94/6293 | 177/18723 | 6.62e-08 | 1.17e-06 | 94 |
GO:0031667210 | Thyroid | ATC | response to nutrient levels | 212/6293 | 474/18723 | 2.37e-07 | 3.70e-06 | 212 |
GO:003629425 | Thyroid | ATC | cellular response to decreased oxygen levels | 85/6293 | 161/18723 | 3.86e-07 | 5.65e-06 | 85 |
GO:005123532 | Thyroid | ATC | maintenance of location | 152/6293 | 327/18723 | 7.84e-07 | 1.04e-05 | 152 |
GO:006053724 | Thyroid | ATC | muscle tissue development | 181/6293 | 403/18723 | 1.27e-06 | 1.62e-05 | 181 |
GO:001076116 | Thyroid | ATC | fibroblast migration | 32/6293 | 47/18723 | 1.42e-06 | 1.77e-05 | 32 |
GO:005165133 | Thyroid | ATC | maintenance of location in cell | 105/6293 | 214/18723 | 1.92e-06 | 2.31e-05 | 105 |
GO:000961225 | Thyroid | ATC | response to mechanical stimulus | 105/6293 | 216/18723 | 3.29e-06 | 3.70e-05 | 105 |
GO:007145624 | Thyroid | ATC | cellular response to hypoxia | 78/6293 | 151/18723 | 3.44e-06 | 3.86e-05 | 78 |
GO:000836122 | Thyroid | ATC | regulation of cell size | 89/6293 | 181/18723 | 1.01e-05 | 1.00e-04 | 89 |
GO:000736915 | Thyroid | ATC | gastrulation | 90/6293 | 185/18723 | 1.54e-05 | 1.43e-04 | 90 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C8A | SNV | Missense_Mutation | rs749738757 | c.281C>T | p.Ala94Val | p.A94V | P07357 | protein_coding | tolerated(0.29) | benign(0.119) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C8A | SNV | Missense_Mutation | novel | c.979T>C | p.Tyr327His | p.Y327H | P07357 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C8A | SNV | Missense_Mutation | c.555G>C | p.Trp185Cys | p.W185C | P07357 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A2LH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
C8A | SNV | Missense_Mutation | rs753968787 | c.332N>A | p.Arg111His | p.R111H | P07357 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-BH-A0E9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C8A | insertion | Frame_Shift_Ins | novel | c.1083_1084insGAACAAAGAGAGC | p.Met362GlufsTer28 | p.M362Efs*28 | P07357 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
C8A | deletion | Frame_Shift_Del | novel | c.1446_1456delNNNNNNNNNNN | p.Arg484GlyfsTer36 | p.R484Gfs*36 | P07357 | protein_coding | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR | ||
C8A | SNV | Missense_Mutation | c.403N>A | p.Ala135Thr | p.A135T | P07357 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
C8A | SNV | Missense_Mutation | rs143726641 | c.1742N>T | p.Thr581Met | p.T581M | P07357 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AA-3856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
C8A | SNV | Missense_Mutation | c.1111N>T | p.Asp371Tyr | p.D371Y | P07357 | protein_coding | tolerated(0.06) | possibly_damaging(0.663) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
C8A | SNV | Missense_Mutation | c.370N>A | p.Gly124Ser | p.G124S | P07357 | protein_coding | tolerated(0.18) | possibly_damaging(0.723) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |